Variables associated with insulin production in persons with type 2 diabetes treated with multiple daily insulin injections

Klara Westman; Henrik Imberg; Henrik Albrektsson; Irl B Hirsch; Jaakko Tuomilehto; Sofia Dahlqvist; Marcus Lind

doi:10.1016/j.pcd.2020.11.005

Variables associated with insulin production in persons with type 2 diabetes treated with multiple daily insulin injections

Prim Care Diabetes. 2021 Jun;15(3):607-613. doi: 10.1016/j.pcd.2020.11.005. Epub 2020 Dec 7.

Authors

Klara Westman¹, Henrik Imberg², Henrik Albrektsson³, Irl B Hirsch⁴, Jaakko Tuomilehto⁵, Sofia Dahlqvist⁶, Marcus Lind⁶

Affiliations

¹ Department of Medicine, NU-Hospital Group, Trollhättan/Uddevalla, Sweden; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: [email protected].
² Statistiska Konsultgruppen, Gothenburg, Sweden; Department of Mathematical Sciences, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden.
³ Statistiska Konsultgruppen, Gothenburg, Sweden.
⁴ University of Washington School of Medicine, UW Medicine Diabetes Institute, Seattle, WA 98109, United States.
⁵ Public Health Promotion Unit, Finnish Institute for Health and Welfare, P.O. Box 30, 00271 Helsinki, Finland; Department of Public Health, University of Helsinki, 00014 Helsinki, Finland; Saudi Diabetes Research Group, King Abdulaziz University, 21589 Jeddah, Saudi Arabia.
⁶ Department of Medicine, NU-Hospital Group, Trollhättan/Uddevalla, Sweden; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

PMID: 33303380
DOI: 10.1016/j.pcd.2020.11.005

Abstract

From the MDI-liraglutide study, we evaluated variables associated with endogenous insulin production in persons with multiple daily insulin injections-treated type 2 diabetes by relating C-peptide, proinsulin and proinsulin/C-peptide ratio at baseline to baseline variables. Lower insulin production was related to longer diabetes duration, shorter abdominal sagittal diameter and more glycaemic variability.

Keywords: C-peptide and proinsulin and related variables; Insulin secretion; Multiple daily insulin injections; Type 2 diabetes mellitus.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2* / diagnosis
Diabetes Mellitus, Type 2* / drug therapy
Glycated Hemoglobin / analysis
Humans
Hypoglycemic Agents / adverse effects
Insulin Infusion Systems
Insulin* / adverse effects
Liraglutide / therapeutic use

Substances

Blood Glucose
Glycated Hemoglobin A
Hypoglycemic Agents
Insulin
Liraglutide